Experimental Design to Predict Process Variables in the Microcrystals of Celecoxib for Dissolution Rate Enhancement Using Response Surface Methodology

被引:3
作者
Jelvehgari, Mitra [1 ,2 ]
Valizadeh, Hadi [1 ,2 ]
Montazam, Seyed Hassan [3 ]
Abbaszadeh, Sanam [4 ,5 ]
机构
[1] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Tabriz, Iran
[3] Islamic Azad Univ, Bonab Unit, Bonab, Iran
[4] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran
[5] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
关键词
Celecoxib; Brij; 35; Microcrystal; Dissolution; Release;
D O I
10.15171/apb.2015.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The purpose of the present investigation was to increase the solubility and dissolution rate of celecoxib (CLX) by preparing microcrystals of drug by solvent change precipitation. Methods: This procedure was optimized in order to obtain stable and homogeneous particles with a small particle size, high yield and fast dissolution rate. CLX agglomerates were prepared with brij35 (stabilizer agent) using acetone as solvent, water as non-solvent, respectively. The agglomerates were characterized by DSC, XRD, FTIR studies. A full-factorial design was employed to study the effect of independent variables, the amounts of stirring rate (X1), volume of organic solvent (X2), volume of aqueous solvent (X3), time of stirring (X4), concentration of Brij (X5), concentration of Tween 80 (X6), concentration of HPMC (X7) on dependent variables, particle size (PS), drug content (DC), drug released after 15 min (Q15), crystal yield (CY), Gibbs free energy change (Delta G degrees tr), antalpy change (Delta H) and saturated solubility (Ss). Results: The DSC and FTIR results indicated the absence of any interactions between drug and stabilizers. These studies showed a decrease in crystalinity in agglomerates. The crystals exhibited significantly improved micromeritic properties compared to pure drug. The drug content and crystal yield were in the range of 32.84-48.22% and 64.55-83.33% with all formulations, respectively. The solubility and drug release rates increased with an increase in concentration of stabilizer. Conclusion: The results show that microcrystals of the drug in stabilizer considerably enhanced the dissolution rate.
引用
收藏
页码:237 / 245
页数:9
相关论文
共 16 条
[1]   Dissolution rate enhancement of the novel antitumoral β-lapachone by solvent change precipitation of microparticles [J].
Cunha-Filho, Marcilio S. S. ;
Martinez-Pacheco, Ramon ;
Landin, Mariana .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 69 (03) :871-877
[2]  
de Azeredo H. M. C., 2005, ALIMENTOS NUTR, V16, P89, DOI DOI 10.1016/J.COPBIO.2007.03.001
[3]   Determination of surface properties and how characteristics of salbutamol sulphate, before and after micronisation [J].
Feeley, JC ;
York, P ;
Sumby, BS ;
Dicks, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 172 (1-2) :89-96
[4]  
Gupta Venkadari Rammohan, 2007, Acta Pharmaceutica (Zagreb), V57, P173, DOI 10.2478/v10007-007-0014-8
[5]   Biodegradable nanoparticles for drug delivery and targeting [J].
Hans, ML ;
Lowman, AM .
CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE, 2002, 6 (04) :319-327
[6]   Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide [J].
Jacobs, C ;
Kayser, O ;
Müller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) :161-164
[7]  
Mansouri M., 2011, OPEN C P J, V2, P88, DOI [10.2174/2210289201102010088, DOI 10.2174/2210289201102010088]
[8]   THE EFFECT OF PARTICLE-SIZE AND SHAPE ON THE SURFACE SPECIFIC DISSOLUTION RATE OF MICROSIZED PRACTICALLY INSOLUBLE DRUGS [J].
MOSHARRAF, M ;
NYSTROM, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 122 (1-2) :35-47
[9]   Nanosuspensions for the formulation of poorly soluble drugs - I. Preparation by a size-reduction technique [J].
Muller, RH ;
Peters, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 160 (02) :229-237
[10]   Celecoxib-cyclodextrin systems: Characterization and evaluation of in vitro and in vivo advantage [J].
Nagarsenker, MS ;
Joshi, MS .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (02) :169-178